

POSTER PRESENTATION



The evolution and clinical importance of scar in hypertrophic cardiomyopathy - a 7 year CMR follow-up study

Giovanni Quarta^{1*}, Agata Grasso², Ferdinando Pasquale¹, Andrew S Flett¹, Dan Sado¹, Elena b³, Cono Ariti⁴, Sanjay K Prasad², Perry M Elliott¹, James C Moon¹

From 2011 SCMR/Euro CMR Joint Scientific Sessions Nice, France. 3-6 February 2011

Introduction

Fibrosis is a key histopathological component of hypertrophic cardiomyopathy (HCM). Fibrosis, detected by CMR late gadolinium enhancement (LGE) contributes to diastolic dysfunction, ischaemia, atrial fibrillation, progression to heart failure, sudden cardiac death and is associated with exercise intolerance.

Purpose

We sought to track long term changes in LGE by CMR in HCM and understand its clinical significance.

Methods


Sixty patients with HCM underwent CMR in 2001-2003. Twelve of these patients (age 42.0 ± 18.7 years) underwent two CMRs at least 6 years apart (mean 7.4 ± 0.4 years). Follow up was not completed in the other 48 due to: 6 deaths, 1 cardiac transplantation, 17 device implantations (ICD, PPM), 8 declined; 6 lost to follow up; 4 had a normal follow-up scan; 6 index CMR not available. Morphological parameters (maximal wall thickness, LV mass, EF, LV volumes, LA size, SAM, LVOT obstruction) were measured by two independent observers. The entire short-axis LGE stack of images were analyzed quantitatively with MRI-MASS (Medis, Leiden, The Netherlands, FWHM technique to calculate LGE% total and per segment).

Results

Five patients (42%) had no LGE at baseline and three of these had none at follow-up. In all other patients, LGE


 $^1 \mbox{University}$ College London Hospitals Trust, London, UK Full list of author information is available at the end of the article

either appeared *de-novo* (two) or increased during followup (mean difference $20\pm14\%$, range 5-52%). Baseline LGE correlated with adverse remodelling: decrease in maximal wall thickness (linear association, p=0.001) and LV mass (linear association, p=0.05); LV EF tended to decrease and





© 2011 Quarta et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



LVEDV tended to increase with increasing LGE at baseline, but did not reach statistical significance. The presence of LGE at baseline was strongly associated with worsening of LGE at follow up (R^2 =0.64, p=0.002). By segmental analysis, LGE increased on average by 13.8±22.5%, (p<0.001). The amount of LGE in the segment at baseline and the total percent of LGE at baseline were strongly associated with the amount of LGE at follow up (R^2 =0.54, p<0.001). Segmental baseline %LGE was strongly associated with the increase of LGE (p=0.016). Figures 1 and 2

Conclusions


Over 7 years, HCM LGE increases. Baseline LGE predicts adverse remodelling. LGE begets LGE - with baseline LGE predicting future increases in LGE.

Author details

¹University College London Hospitals Trust, London, UK. ²Cardiovascular Magnetic Resonance, Royal Brompton and Harefield NHS Foundation Trust, London, UK. ³Azienda Ospedaliera "Spedali Civili", Brescia, Italy, ⁴London School of Hygiene and Tropical Medicine, London, UK. ⁴London School of Hygiene and Tropical Medicine, London, UK.

Published: 2 February 2011

doi:10.1186/1532-429X-13-S1-P296 **Cite this article as:** Quarta *et al.*: The evolution and clinical importance of scar in hypertrophic cardiomyopathy - a 7 year CMR follow-up study. *Journal of Cardiovascular Magnetic Resonance* 2011 **13**(Suppl 1):P296.



- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

BioMed Central